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Abstract 
Prescription of tenofovir disoproxil fumarate (TDF) for patients with baseline creatinine clearances 
(CrCl) <60ml/min is said to increase risk of further decline in CrCl. Study objectives were to assess 
incidence of improvement and predictors thereof; to assess incidence of decline and transition to 
lower stages of CrCl; and comparison of declines between patients with a baseline CrCl <60ml/min 
(group-I) and ≥60ml/min (group-II). The study was retrospective, included patients 16yrs or older 
who received TDF-containing ART. Improvement and decline were defined as ≥25% increase or 
decrease in CrCl, respectively. Binary logistic regression was performed to identify predictors of 
improvement.  Groups I and II had 2861 and 7526 patients, respectively. In group-I, improvement in 
CrCl was observed in 40.1% (n=1,146), and was associated with stage IV of CrCl (adjusted Odds 
Ratio [aOR]=13.4 [95%CI: 6.7 – 26.9, p<0.001]); male gender (aHR=1.8 [95%CI: 1.5 – 2.2, 
p<0.001]); and a poor HIV-status  (aHR=1.2 [95%CI: 1.0 – 1.4], p=0.033). In groups-I and group-II, 
respectively, decline occurred in 2.3% and 13.0%, (p<0.001); transition to lower stages occurred in 
1.0% and 25.2% (p<0.001); and  migration to stage IV CrCl occurred in  1.0% and 0.5% (p<0.001). 
Improvement was more likely than decline in group-I patients.  Although, group-I patients were more 
likely to experience new onset severe reduced CrCl than group-II patients, the proportions were 
extremely low. TDF should not be withheld from HIV-positive patients with a baseline CrCl 
<60ml/min. 
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Background 
During the pre-antiretroviral therapy (ART) era, HIV-related renal impairment was a relatively 
frequent morbidity and cause of mortality, especially in patients of African descent (1–3). However, 
the frequency of HIV-related renal impairment, was appreciably reduced when ART was introduced 
(4,5). Nowadays, ART naïve patients who present with moderate or severe reductions in renal 
function are likely reporting late for treatment and care, or are poorly adherent to ART (6). ART has 
been shown to improve renal function in these patients (7–9). From 2010, in Namibia, to the time of 
writing this manuscript, tenofovir disoproxil fumarate (TDF)–containing ART regimens have been 
preferred over other regimens because of TDF’s better safety profile (10–13). Nevertheless, TDF is an 
independent risk factor for nephrotoxicity (9,14,15). Because of TDF-related nephrotoxicity, 
Namibia’s 2016 ART guidelines recommended the prescription of an alternative to TDF when the 
HIV-positive patient had a baseline CrCl <60ml/min (11). On the contrary, the guidelines allowed the 
prescription of TDF-containing ART for patients with a baseline CrCl <60ml/min, if they were co-
infected with hepatitis-B (11), which is relatively frequent in Namibia (16). The results of a recent 
study we conducted, albeit in a few patients from one facility, suggested that improvement is expected 
in HIV-infected patients who receive TDF containing ART with a baseline CrCl <60 ml/min (17). 
The primary objective of this study was to confirm, with a larger number of patients, whether the 
initiation of TDF containing ART was associated with improvement or an increased risk of worsening 
renal function in patients who had their CrCl in the moderate/severe stage, at baseline. The secondary 
objectives were to identify the factors that were associated with the improvement in renal function, 
and to compare the CrCl decline rates between the patients who had a moderate/severe reduced CrCl 
and those who had mildly reduced/normal CrCl at baseline. 
Methods 
Study design and inclusion criteria  
This was a retrospective cohort study that included patients who initiated TDF-containing ART from 
August 2010 to December 2016, because TDF-containing ART became the preferred initial ART 
regimen in Namibia in July 2010 (18). Secondly, patients who were 16 years and older at the time of 
ART initiation were included, as recommended in the guidelines (18). Thirdly, patients whose renal 
function stage was moderate/severe reduced were included for the primary analysis. The secondary 
analysis was a comparison of the rates of adverse renal outcomes between the patients who had a 
moderate renal function at baseline, and those who had mild/normal CrCl at baseline. The Namibia 
ART guidelines recommend the use of Cockcroft-Gault’s equation to calculate CrCl.(18) The 
equation is as follows: 
𝐶𝑟𝐶𝑙 = (140 − 𝑎𝑔𝑒 [𝑦𝑒𝑎𝑟𝑠]) ∗
𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝑆𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 (𝜇𝑚𝑜𝑙𝑒 𝑝𝑒𝑟 𝐿)
∗ 1.22 
For female patients, the value generated from the above equation is multiplied by 0.85. NB: The 
pharmacists at the health facilities calculate and record the CrCl results in the patient’s file (not 
published). Serum creatinine is measured by the Namibia Institute of Pathology, which has a 
functional lab at each public health hospital in Namibia.  
 
Setting  
The study depended on data from two intermediate referral hospitals: Oshakati Intermediate Hospital, 
a 750-bed capacity hospital in Northern Namibia, and Katutura Intermediate Hospital, an 830-bed 
capacity hospital in Windhoek, the capital city of Namibia. Together, these hospitals provided HIV 
treatment and care to over 40,000 patients, according to the data that was accessed from the Ministry 
of Health and Social Services (MoHSS) for this study.  
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Study variables 
Independent variables 
The independent variables included gender, age, weight, follow-up duration, ART regimen, 
pregnancy, stage of renal function, and status of HIV infection. Status of HIV infection was 
dichotomous in nature: undesired status of HIV infection and desired status of HIV infection. 
Undesired status of HIV infection constituted a CD4 count <200 cells/mm3 or a viral load >1000 
copies/mL or tuberculosis (TB) or a combination of these variables. We used a CD4 count <200 
cells/mm3, because this is when opportunistic infections and other HIV-related diseases escalate and 
can be an indicator of treatment failure (19–21). We used a viral load >1000 copies/ml, because 
treatment failure is defined  as a viral load >1000 copies/mL at 24 weeks of ART (22–24). Lastly, we 
included tuberculosis as it is a known indicator of treatment failure (25). 
Dependent variables (Endpoints) 
The endpoints of the study were: 
1.  Improvement in CrCl 
  Improvement in CrCl was defined as an increase in CrCl by ≥25% based on the 
difference between the baseline and last measured CrCl. Additionally, an increase in 
CrCl by ≥3ml/min/year was investigated.  
2. Decline in CrCl 
 Decline in CrCl, was defined as a ≥25% reduction in CrCl, relative to the baseline. 
3. Transition from baseline to lower stages of CrCl in general.  
 These included transitions from stages I and II to stages III and IV; and from stage III 
to stage IV.  
 The stages of CrCl and their limits, were stage I (≥90 ml/min); stage II (60 – 89 
ml/min); stage III (30 – 59 ml/min); and stage IV (<30 ml/min)].  
4. Transition to stage IV of CrCl.  
 This included from a baseline CrCl ≥60 ml/min (stages I and II) to stage IV; and from 
stage III to stage IV  
Data analysis 
The characteristics of CrCl <60 ml/min group were described using means and standard deviations 
(SD) for continuous variables and proportions for categorical variables. The difference in CrCl 
between the baseline and the last recorded value was used to determine whether improvement or 
decline in CrCl had occurred. Then the <60 ml/min group of patients were sub-divided into the 
improvement and non-improvement groups. The means (SD) and proportions in the improvement and 
non-improvement groups were used for descriptive purposes. The proportion of patients who 
experienced decline in CrCl amongst the <60 ml/min group and the corresponding proportion 
amongst the ≥60 ml/min group were calculated.   
For the <60 ml/min group of patients, we compared the means (SD) and proportions of patients in the 
improvement group with the corresponding means and proportions in the non-improvement group. 
We used the student’s t-test for continuous variables, and Pearson’s chi-square test for categorical 
variables. To identify the variables that were associated with improvement in CrCl, we performed 
binary logistic regression analysis. First, we conducted univariate analysis for each independent 
variable. Then we included all the independent variables in the multivariate analysis model, which we 
performed using the backward stepwise conditional method. This method eliminates variables from 
the model based on the likelihood-ratio statistic on conditional parameter estimates (26,27). As such, 
only variables that met the pre-set conditions of significance, were left in the final step of the 
multivariate analysis model.   
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We conducted sub-analysis estimates of the mean duration of follow-up for the improvement and non-
improvement groups for the first four time-intervals. These time-intervals were included, because one 
could confirm that improvement had occurred in the first-two time intervals (0 – 6 months & 7 – 12 
months), while for the second two time-intervals (13 – 18 months & 19 – 24 months), improvement 
could have occurred in the first two time-intervals. For each improvement group, we compared the 
duration of follow-up for the improvement group and the non-improvement group, using Levene’s 
test to assess similarity of variances, and the independent students t-test for the difference means. 
(NB: The day the last CrCl was recorded served as the end of follow-up period.) We conducted binary 
logistic regression sub-analysis, to compare with the results that were generated for the original 
analysis.   
Next, we compared the proportion of patients who experienced the ≥25% decline in CrCl amongst the 
<60 ml/min group with the corresponding proportion amongst the ≥60 ml/min group using the 
Student’s t-test, and assessed the proportion of patients who experienced a shift to lower stages of 
CrCl. We evaluated the proportions who shifted to stage IV CrCl between the <60 and ≥60 ml/min 
groups. (NB: For the group who had a baseline CrCl from 30 - <60 ml/min, the lower stage of renal 
function was stage IV CrCl: <30 ml/min. For the group who had a baseline CrCl ≥60 ml/min the 
lower stages included: stage III CrCl (CrCl 30 – 59 ml/min), and stage IV CrCl (<30 ml/min). All 
analyses were conducted using SPSS version 22. The p-value was set at <0.05 and the confidence 
interval at 95%. 
Ethics 
The study was approved by the Faculty of Health Sciences, the ethics review board of the University 
of Namibia, and the MoHSS. The study’s reference number at the MoHSS is 17/3/3. There was no 
contact with the patients, and there was no involvement of health care workers. Anonymity of the 
patients was assured by eliminating any patient identifier data. The data were only available to the one 
of the researchers.  
Results 
A total of 10,388 patients were included in the study (Figure 1). They were divided into two groups 
based on the baseline CrCl. The first group consisted of patients with a baseline CrCl <60 ml/min 
(n=2,862, 27.5%), and the second group consisted of patients with a baseline CrCl ≥60 ml/min 
(n=7,526, 72.5%).  Most were female (67.6%), and this was the case for both groups, although the 
proportion of females in the first group was significantly greater than in the second group. The 
cohort’s mean (SD) age was 38 years, but the mean age of the first group was approximately three 
years younger than the second group (p<0.001). The mean weight of the cohort was 63.7kg, and no 
difference was found between the groups (p=0.631). The mean CrCl at baseline was 63.2 ml/min, but 
the first group’s mean baseline CrCl was significantly lower than that of the second group (p<0.001). 
The duration of follow-up was 2.2 years, and there was no difference between groups (p=0.326). The 
mean follow-up CrCl was 67 ml/min, which was 3.8 ml/min above the baseline. Although the first 
group still had a significantly lesser CrCl than the second group, their follow-up CrCl was ~12 ml/min 
above their baseline CrCl, while for the second group the follow-up CrCl was 4 ml/min lower than 
their baseline CrCl.  Approximately 39% had a poor HIV status, but the first group had a significantly 
less proportion of these cases (p=0.013). There were about 1.9% records of pregnancy, but the first 
group had a significantly higher proportion than the second (p=0.003). We found few cases of 
hepatitis-B surface antigen, and there was no difference between the groups (p=0.515). A sum of 
13.5% had received isoniazid preventive therapy (IPT), but the first group had fewer cases than the 
second group (p=0.017). Few patients (5.9%) were receiving ART regimens containing TDF and a 
protease inhibitor (PI), but there were fewer patients in the first group than the second group 
(p=0.011).  The general trend was an increase in CrCl for patients in the first group. The opposite was 
true for patients in the second group (Figure 2).  
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Figure 1: Selection of patients for the assessment of improvement and decline in CrCl 
 
 
6 
 
Table 1: Characteristics of the patients in the study, and changes in renal function 
Variable All patients (n=10,388): 
n (%)  
Moderate/severe  
group (n=2862):  
n (%)  
Mild/normal 
 group (n=7526): 
 n (%)  
p-value 
Age (years, mean (SD)   38.0 (9.3) 36.5 (9.1) 39.4 (9.4) <0.001 
weight (kg), mean (SD)   63.3 (13.8) 62.9 (14.0) 63.7 (13.6) 0.631 
Duration of follow-up (years), mean (SD)   2.2 (1.7) 2.1 (1.7) 2.2 (1.7) 0.326 
Baseline CrCl (ml/min)  63.2 (12.0) 50.9 (8.7) 75.5 (15.2) <0.001 
Follow-up CrCl  67.0 (14.5) 62.7 (13.7)) 71.2 (15.2) <0.001 
Gender Female 7021 (67.6) 2402 (83.9) 4619 (61.4) <0.001 
Male 3367 (32.4) 460 (16.1) 2907 (38.6)  
HIV status marked with a CD4 count <200 or VL 
>1000 or TB or a combination of either   
Yes 3988 (39.0) 1044 (36.5) 2944 (39.1) 0.013 
No 6400 (61.0) 1818 (63.5) 4582 (60.9)  
Pregnancy Yes 198 (1.9) 73 (2.6) 125 (1.7) 0.003 
 No 10190 (98.1) 2789 (97.4) 7401 (98.3)   
Hepatitis-B surface antigen positive Yes 55 (0.5) 13 (0.5) 42 (0.6) 0.515 
 No 10333 (99.5) 2849 (99.5) 7484 (99.4)  
Used Isoniazid preventive therapy Yes 1398 (13.5) 348 (12.2) 1050 (14.0) 0.017 
No 8990 (86.5) 2514(87.8) 6476 (86.0)  
Improvement in renal function (≥25% increase in 
CrCl) 
Yes 1678 (16.2) 1147 (40.1) 531 (7.1) <0.001 
No 8710 (83.8) 1715(59.9) 6995 (92.9)  
Any improvement renal function (≥3ml/min/year 
increase in CrCl) 
Yes 4305 (41.4) 2065 (72.2) 2240 (29.8) <0.001 
No 6083 (58.6) 797 (27.8) 5286 (70.2)  
Decline in renal function (≥25% decrease in 
CrCl) 
Yes 1040 (10.0) 65 (2.3) 975 (13.0) <0.001 
No 9348 (90.0) 2797 (97.7) 6551 (87.0)  
Any decline (≥3ml/min/year) Yes 3085 (29.7) 201 (7.0) 2884 (38.3) <0.001 
No 7303 (70.3) 2661 (93.0) 4642 (61.7)  
Receiving Ritonavir along with TDF Yes 608 (5.9) 140 (4.9) 468 (6.2) 0.011 
No 9780 (94.1) 2722 (95.1) 7058 (93.8)  
Regression to lower stage of renal function Yes 1929 (18.6) 29 (1.0) 1900 (25.2) <0.001 
No 8459 (81.4) 2833 (99.0) 6626 (74.8)  
Regression to severe stage of renal function Yes 63 (0.6) 29 (1.0) 34 (0.5) 0.001 
No 10325 (99.4) 2833 (99.0) 7492 (99.5)  
*CD4 count<200 mm3, VL >1000 copies/L and Tuberculosis
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Figure 2: Baseline and follow-up CrCl for patients according to stage of CrCl at baseline 1 
 2 
Of the 2,862 patients in the first group, improvement in CrCl occurred in 40.1% (n=1,147), who were 3 
referred to as the improvement group. The rest formed the non-improvement group. The non-4 
improvement group included patients who had >3ml/min/year increases in CrCl for who the follow-5 
up CrCl was <25% above the baseline CrCl, and those who experienced any decline in CrCl. Most 6 
patients had two CrCl records (Figure 3: panels A and B, for improvement and non-improvement 7 
groups, respectively). The follow-up CrCl results were spread across time-intervals (Figure 3).The 8 
improvement group were older (p=0.015); had a longer duration of follow-up (p<0.001), a lower 9 
baseline CrCl (p<0.001), a greater proportion of male patients (p<0.001), and less pregnancy events 10 
than the non-improvement group (p<0.001) (Table 2). Further, the improvement group had non-11 
significantly higher proportions of patients with a CD4 count <200 cells/mm3, a viral load >1000 12 
copies/L, and non-significantly lower proportions with tuberculosis (TB), which culminated in a 13 
greater proportion of patients with a poor HIV-status than the non-improvement group (p=0.032) 14 
(Table 2.) The follow-up mean CrCl of the improvement group was higher than their baseline by 26.0 15 
ml/min, while for the non-improvement group it was 2.3 ml/min higher than their baseline. The 16 
follow-up CrCl of the improvement group was significantly greater than that of the non-improvement 17 
group (Table 2). The sub-analysis, which included 1788 patients, showed that the mean duration of 18 
follow-up was significantly shorter for the improvement group than for the non-improvement group 19 
(Table 3): a deviation from the findings for the whole group (n=2862), (Table 2). 20 
 21 
Figure 3: Distribution of patients in the improvement group (panel A) and non-improvement 22 
group (panel B) according to the number of CrCl result recorded 23 
 24 
 25 
Multivariate binary logistic regression analysis for the 2862 patients showed that male patients were 26 
1.8 times more likely to experience improvement in CrCl than females (p<0.001); that patients who 27 
were in stage IV of CrCl, were 13.4 times more likely to experience improvement than patients who 28 
were in stage III of CrCl (p<0.001); that for every additional year of ART, the odds of experiencing 29 
improvement in CrCl were 1.1 (p<0.001); and that patients who were in a poor HIV status, were 1.2 30 
times more likely to experience improvement than their counterparts (p<0.001), (Table 2). The 31 
regression analysis was repeated for the sub-group, which generated similar results for all predictor 32 
variables, except duration of follow-up for which the effect was reversed: from an OR of 1.1 to 0.7.  33 
 34 
Figure 4: Test results distributed unequally across the time intervals 35 
 36 
 37 
The proportion of events of 25% decline in CrCl amongst the <60 ml/min group was lower than the 38 
corresponding proportion in the ≥60 ml/min group (p<0.001) (Table 1).  Similarly, the transition to 39 
lower stages of CrCl in the <60 ml/min group was lower than in the ≥60 ml/min group: 1.0% vs. 40 
25.2%; p<0.001, (Table I). Nonetheless, more patients from the <60ml/min group than from the ≥60 41 
ml/min group transitioned to CrCl stage IV (Table 1)42 
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Table 2: Factors associated with CrCl improvement in patients with baseline CrCl less than 60ml/min 
Variable Improvement 
group 
Non-
improvement 
group 
p-
value 
Crude Odds Ratio 
(Confidence Interval) 
P-value Adjusted Odds Ratio 
(Confidence Interval) 
P-value 
Age (years, mean (SD)  37.1±9.3 36.2±8.9 0.015 1.0 (1.0 – 1.0) † 0.009 - - 
weight (kg), mean (SD)   62.7±13.7 63.0±14.2 0.568 1.0 (1.0 – 1.0) † 0.580 - - 
Duration of follow-up (years), mean (SD)  2.3±1.9 2.0±1.6 <0.001 1.1 (1.06 – 1.2) <0.001 1.1 (1.06 – 1.2) <0.001 
 0.9±0.6⸸ 1.1±0.6⸸ <0.001 0.7 (0.6 – 0.8) ⸸  0.7 (0.6 – 0.8) ⸸  
Baseline CrCl (ml/min) 46.0±10.7 54.2±5.0 <0.001 - - - - 
Follow-up CrCl  72.0±14.1 56.5±9.2 <0.001 - - - - 
Gender, Male Yes 896 (78.2) 1505 (87.8) <0.001 2.0 (1.6 – 2.4) 
1.6 (1.2 – 2.0) ⸸ 
<0.001 1.8 (1.5 – 2.2) 
1.4 (1.03 – 1.8) ⸸ 
<0.001 
No 250 (21.8) 210 (12.2)  1.0 (reference)    
HIV status‡  Yes 451 (39.4) 607 (35.4) 0.032 1.2 (1.1 – 1.4) 
1.5 (1.2 – 1.8) ⸸ 
0.010 
<0.001 
1.3 (1.1 – 1.5) 
1.4 (1.2 – 1.8) ⸸ 
0.007 
<0.001 
No 695 (60.6) 1108 (64.6)  1.0 (reference)    
Stage IV CrCl Yes 82 (90.1) 9 (9.9) <0.001 14.6 (7.3 – 29.1) <0.001 13.4 (6.7 – 26.8) <0.001 
     12.1 (5.7 – 25.7)⸸ <0.001 12.5 (5.8 – 26.7) ⸸ <0.001 
 No 1065 (38.4) 1706 (61.6)  1.0 (reference)    
Pregnancy Yes 18 (1.6) 54 (3.1) 0.008 0.5 (0.3 – 0.9) 0.015   
 No 1128 (98.4) 1661 (96.9)  1.0 (reference)    
Hepatitis-B surface antigen positive Yes 6 (0.5) 7 (0.4) 0.652 1.3 (0.5 – 3.8) 0.241 - - 
 No 1140 (99.5) 1708 (99.6)  1.0 (reference)    
Used Isoniazid preventive therapy Yes 167 (14.6) 263 (15.3) 0.582 0.9 (0.7 – 1.1) 0.323 - - 
 No 978 (85.4) 1452 (84.7)  1.0 (reference)    
Receiving Ritonavir along with TDF Yes 64 (5.6) 76 (4.4) 0.161 1.4 (0.9 – 2.0) 0.123 - - 
 No 1082 (94.4) 1639 (95.6)  1.0 (reference)    
CD4 count <200 cells/mm3§ Yes 191 (16.7) 248 (14.5) 0.109 - - - - 
 No 955 (83.3) 1467 (85.5)      
Viral load >1000 copies/L§ Yes 246 (21.5) 322 (18.8) 0.077 - - - - 
 No 900 (78.5) 1393 (81.2)      
Tuberculosis§ Yes 111 (9.7) 172 (10.0) 0.763 - - - - 
 No 1035 (90.3) 1543 (90.0)      
Improvement (≥25% increase in CrCl)  1146 n/a - - - - - 
Any improvement (≥3ml/min/year 
increase in CrCl) 
 1146 582 - - - - - 
Any decline (≥3ml/min/year)  n/a 201 - - - - - 
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Variable Improvement 
group 
Non-
improvement 
group 
p-
value 
Crude Odds Ratio 
(Confidence Interval) 
P-value Adjusted Odds Ratio 
(Confidence Interval) 
P-value 
Decline in renal function (≥25% decrease 
in CrCl) 
 n/a 65 - - - - - 
Regression to severe stage of renal 
function 
 n/a 28 - - - - - 
‡HIV status marked with a CD4 count <200 or VL >1000 or TB or a combination of either of these variable (Poor status = Yes); †means -figures were rounded off; ⸸Sub-
analysis findings, which involved 62.5% of the patients (n=1788); §= variables marked with this symbol were not used in the model as they contributed to the HIV status variable. The 
italicised values are findings generated from the sub-analysis. 
 
   
 
Table 3: Sub-analysis: Duration of follow-up for the improvement group vs. non-improvement group based on different time-points  
Duration of follow-up Number of patients p-value 
(t-test) 
 Duration of follow-up: mean 
(SD), years 
F-value p-value 
(F-test) 
p-value 
(t-test) 
Improvement Non-
improvement 
Improvement  Non-
improvement  
0-6 months Female 265 (58.6) 187 (41.4) 0.352 0.22 (0.15) 0.3 (0.2) 0.099 0.753 0.012 
 Male 43 (53.1) 38 (46.9)       
7-12 months Female 174 (63.7) 99 (36.3) 0.049 0.8 (0.2) 0.8 (0.2) 2.186 0.140 0.540 
 Male 19 (47.5) 21 (52.5)       
13-18 months Female 241 (63.9) 136 (36.1) 0.027 1.3 (0.2) 1.3 (0.2) 0.024 0.876 0.994 
 Male 19 (46.3) 22 (53.7)       
19-24 months Female 308 (71.5) 123 (28.5) 0.033 1.7 (0.1) 1.7 (0.1) 0.792 0.374 0.956 
 Male 56 (60.2) 37 (39.8)       
0-24 months Female 988 (64.4) 545 (35.6) 0.001 0.9 (0.6) 1.1 (0.6) 1.169 0.280 <0.001 
 Male 137 (53.7) 118 (46.3)       
More male patients experienced improvement at all time- intervals except the first one, where no difference in proportions was observed. The duration of follow-up was significantly shorter for 
the patients who experienced improvement than for the corresponding group. Most patients in the improvement group had the second test results recorded after 24 months, widely spread across 
the time intervals. The event of improvement could not be traced to a specific time interval. For this reason, they were not included in the sub-analysis.
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Discussion 1 
This in-depth assessment of the effects of TDF-containing ART on renal function in HIV-positive 2 
patients with a baseline CrCl of <60 ml/min, involved two referral hospitals and included many 3 
patients. We found that a large proportion of patients experienced improvement in CrCl following the 4 
initiation of ART (TDF-containing). The factors that were associated with improvement in CrCl 5 
included stage IV of CrCl at baseline, male gender, and a poor HIV status. We found that decline in 6 
CrCl was more frequent amongst patients with a baseline CrCl ≥60 ml/min than in those with a 7 
baseline CrCl <60 ml/min. We found that disproportionately more patients in the ≥60 ml/min group 8 
transitioned to lower stages of CrCl; however, disproportionately fewer patients in the ≥60 ml/min 9 
group than in the <60 ml/min, transitioned to stage IV of CrCl.   10 
Our study documents a significantly greater proportion of patients experiencing improvement than 11 
decline in CrCl following the initiation of ART, moreover they received TDF-containing ART. These 12 
findings agree with a previous study we conducted on fewer patients (17). Mulenga et al., observed 13 
improvement in renal function for patients with severe renal impairment at baseline, even with TDF-14 
containing ART (8). We found that improvement in CrCl was an early event, and this has been 15 
implied by Mpondo et al. and Kalayjian (7,28). In our study, most patients had two renal function test 16 
results including the baseline and the second test, but the second test results were spread across 17 
various time intervals making it a challenge to assess the effect of duration of exposure to the outcome 18 
of interest. The sub-analysis we conducted to sort out this challenge exposed an interaction bias, as 19 
the direction of effect was reversed. The latter finding was more likely than the former because we 20 
found improvement within the first year for most patients who had more than two renal function test 21 
results.  Since renal impairment is a complication of HIV, the improvement we observed suggests that 22 
some patients in the <60 ml/min group were experiencing HIV-related renal impairment, which 23 
responds to highly active ART (29). This preposition leans on the fact that the likelihood of 24 
experiencing improvement amongst patients in CrCl stage IV at baseline was several folds that of the 25 
patients who were in stage III of CrCl. HIV is known to cause HIVAN, HIV immune complex kidney 26 
disease, and opportunistic infections in the parenchyma of the kidney, which affect kidney function 27 
(6,30–34). Currently, an alternative antiretroviral drug to TDF has been recommended for patients 28 
with a CrCl <60 ml/min as a precautionary measure against further decline (13). However, the 29 
available alternatives, namely zidovudine (AZT) and Stavudine (D4T), are associated with severe 30 
adverse events that have led to their withdrawal from the preferred ART regimens, in favour of TDF; 31 
and sometimes they are contraindicated. For example:  AZT is contraindicated in patients with severe 32 
anaemia at baseline (35). Further, the significantly greater improvement than decline we observed, 33 
suggests that the prescription of TDF for patients with a CrCl <60 ml/min was clinically logical 34 
(7,29), and careful matching of the dose with the CrCl should be ensured. Close monitoring of renal 35 
function in these patients may be necessary, due to TDF-associated nephrotoxicity (18,36), and 36 
bearing in mind that the period of exposure was relatively short. Also, comorbidities that may be 37 
associated with further decline should be investigated prior to initiating TDF-containing ART. We 38 
could not explain why male gender was associated with a significantly greater proportion of 39 
improvement events, but it could be a result of disturbance in the female patients’ hormonal milieu, 40 
resulting in hypoestrogenaemia and loss of  oestrogen’s renal protective effects (37). Further, 41 
regarding male gender, their older age may have influenced the age variable making older age a 42 
predictor of improvement. This is unlikely, because increase in age is associated with a reduction in 43 
the number of functional nephrons (38). A separate analysis on male patients showed that older age 44 
was not a predictor for improvement. A similar analysis on female gender supported the association 45 
between increasing age and improvement, and this increased the likelihood of an unknown 46 
confounding variable. 47 
 48 
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TDF is aetiologically related to nephrotoxicity (39,40), and mechanisms of TDF-associated 1 
nephrotoxicity have been suggested (41,42). Nonetheless, through this study we endeavour to answer 2 
the question ‘what is the incidence rate’, and the question ‘who is at risk regarding the baseline CrCl?’ 3 
This is important because of conflicting evidence regarding both incidence and risk factors 4 
(8,9,43,44), and because the findings pertain to sub-Saharan Africa, where there is a low research 5 
output, except in South-Africa (45). Regarding the question on incidence rate, our study has shown 6 
that TDF-associated nephrotoxicity per-se is common, but not all events were clinically significant. 7 
Regarding the question ‘who is at risk’, our study has shown that patients with a baseline CrCl ≥60 8 
ml/min were at a greater risk of experiencing the decline compared with those who had <60 ml/min, 9 
and that not all declines were clinically important. Therefore, the more important outcome to study 10 
would be a transition to stage IV of CrCl, including end-stage-renal-disease, rather than decline in 11 
CrCl. A study by Ojeh et al put the incidence of TDF-associated renal impairment at 4.6% (46), but 12 
did not provide the proportion who migrated to the severe stage of renal function. Brennan et al 13 
reported that patients with a moderate renal function at baseline were more at risk of nephrotoxicity 14 
than others (47). Our findings agree with Brennan et al regarding the risk; but the proportion was too 15 
low to undermine the benefits of TDF-containing ART. The incidence of new onset severe reduced 16 
CrCl in the ≥60 ml/min group  in this study (0.5%) is similar to findings by Kyaw et al (0.3%), 17 
Winston et al (0.43%) and Nishijima et al (0.5%) (48–50). Our study puts the incidence of new onset 18 
severe reduced CrCl at 1.0% amongst patients with a CrCl in the moderate CrCl stage, at baseline. 19 
Further investigation of this that deals with confounders such as diabetes mellitus and hypertension 20 
can generate better results (51). Improvement for female patients being significantly lower than that of 21 
the males could be due to HIV-associated disturbances in the hormonal milieu amongst the female 22 
patients, resulting in ovarian insufficiency. The resultant hypoestrogenaemia is associated with loss of 23 
the renal protective effects of oestrogen (52,53). The findings of this study support the use of TDF-24 
containing ART in patients with moderately or severely reduced CrCl at baseline, particularly in 25 
patients without co-existing diseases known to affect renal function.   26 
The findings of this research provide a solution to the clinician caring for an individual ART naïve 27 
HIV positive patient with a low CrCl. The patient may be coinfected with hepatitis B thus needing 28 
TDF-containing ART (13,54) or may have attending clinical states rendering the use of alternatives to 29 
TDF contraindicated. Our study supports the use of TDF in these patients; however, some patients 30 
may have co-morbidities that increase their nephrotoxicity (55). Therefore, the decision to use TDF-31 
containing ART should be individualised. Careful attention should be given to TDF’s dose, matching 32 
it with the increasing CrCl. Furthermore, the clinician should set one’s attention on the estimated CrCl 33 
rather than the magnitude of reduction, since some large reductions in CrCl never required changes in 34 
dose or dosage intervals. Individualisation of therapy falls under clinical pharmacology. Therefore, 35 
this research is suitable for publication in this journal. 36 
Our study had limitations. Regarding improvement, the definition there of was restrictive. As a result, 37 
a substantial number of patients who experienced increases in CrCl were not included amongst the 38 
improvement group, and may infringe on the benefits of TDF-containing ART. We conducted a 39 
separate analysis including these patients, which generated the same results concerning the predictors. 40 
Another limitation was the various and irregular periods of follow-up, which made it difficult to 41 
assess specific periods such as at six and twelve months, for many patients. In response, we conducted 42 
assessment based on time intervals, for the patients whose follow-up renal function test results were 43 
conducted within two years, including those who had more than one test results. Regarding decline in 44 
CrCl our study was limited by the lack of objective evidence to explain why the declines occurred in 45 
the <60 ml/min group. Nonetheless, TDF has the propensity to cause a significant decline in CrCl, 46 
and a synergistic interaction between TDF and co-existing non-HIV related risk factors are known 47 
aetiologies for the decline in CrCl (41,46,56–58).  48 
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Conclusion 1 
The initiation of TDF-containing ART in patients with a baseline CrCl <60 ml/min was associated 2 
with significantly more patients experiencing improvement than decline. The study suggests that 3 
patients who have HIV-associated renal disease are more likely to improve with ART, including TDF-4 
containing regimens. Improvement should be expected to occur within the early period of ART. Male 5 
gender was also a factor associated with more improvement than female gender. Decline in CrCl 6 
should also be expected but in a rather small proportion of patients who had a CrCl <60 ml/min at 7 
baseline. Careful monitoring may still be required since some of the declines may culminate in new 8 
onset severe reduced CrCl. Overall, this study suggests that TDF-containing ART may be used in 9 
patients with a baseline CrCl <60 ml/min. Although it was not part of this study, it is worth 10 
mentioning that prior to initiating TDF-containing ART, the patients should be investigated for 11 
comorbidities that are known to increase the risk of decline in CrCl. 12 
13 
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